Table 3.

Duration of main clinical symptoms for therapy groups

Symptom	Measure	Favipiravir (N=112)	SOC (N=56)	P-value1
Cough	N	77	38	0.202
	Average	3.64	4.92
	95% CI	3.00; 4.28	3.54; 6.30
Headache	N	91	40	0.794
	Average	8.14	8.50
	95% CI	6.96; 9.33	6.67; 10.33
Dyspnoea	N	50	29	0.281
	Average	3.04	3.69
	95% CI	2.65; 3.43	3.01; 4.37
Myalgia	N	55	17	0.592
	Average	6.36	7.24
	95% CI	5.13; 7.60	5.90; 8.58
Weakness	N	92	47	0.421
	Average	7.54	8.49
	95% CI	6.39; 8.69	6.86; 10.11
Fever	N	85	46	0.244
	Average	3.49	4.57
	95% CI	3.01; 3.98	3.03; 6.10
Decrease of mental activity	N	46	24	0.719
	Average	5.00	5.50
	95% CI	4.12; 5.88	4.08; 6.92
Decrease of physical activity	N	88	43	0.464
	Average	8.59	9.60
	95% CI	7.30; 9.88	7.76; 11.45

¹ P-value was calculated by Student’s t-test. The normality of distribution was assessed by Kolmogorov-Smirnov test (the normality was confirmed).